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 Abstract 
 
Background:  Cognitive impairment and dementia are associated with a range of 
cardiovascular conditions including hypertension, coronary artery disease and atrial 
fibrillation.  We aimed to describe the association with heart failure, summarising 
published data to give estimates around prevalence, incidence and relative risk of 
cognitive impairment/dementia in heart failure. 
Methods:  We searched multidisciplinary databases including MEDLINE (OVID), 
EMBASE (OVID), CINAHL (EBSCO), PsychINFO (EBSCO), Web of Science (Thomson 
Reuters) and CENTRAL (Cochrane Library) from inception until 31st May 2015.  All 
relevant studies looking at cognitive impairment/dementia in heart failure were 
included.  Studies were selected by two independent reviewers using pre-specified 
inclusion/exclusion criteria.  Where data allowed we performed meta-analysis and 
pooled results using random effects models. 
Results:  From 18,000 titles 37 studies were eligible (n=8411 participants).  Data from 
4 prospective cohorts (n= 2513 participants) suggest greater cognitive decline in heart 
failure compared to non-heart failure over the longer term.  These data were not 
suitable for meta-analysis.  In case-control studies describing those with and without 
heart failure (n=4 papers, 1414 participants) the odds ratio for cognitive impairment in 
the heart failure population was 1.67 (95% confidence interval 1.15 -2.42).  Prevalence 
of cognitive impairment in heart failure cohorts (n=26 studies, 4176 participants) was 
43% (95% confidence interval 30-55%). 
Conclusions:  This review suggests a substantial proportion of patients with heart 
failure have concomitant cognitive problems.  This has implications for planning 
treatment and services.  These data do not allow us to comment on causation and 
further work is needed to describe the underlying pathophysiology. 
 
Keywords: Meta-analysis 
 
Page 2 of 31
 Introduction 
The clinical syndrome of heart failure (HF) imposes an immense burden of symptoms 
on patients, reduces quality of life and is one of the leading causes of hospitalisation and 
mortality, particularly in more developed countries.1 Due to aging of the population  and 
improved survival from coronary artery disease (CAD) prevalence of HF is expected to 
double within the next 40 years.2 These arguments of high symptomatic and economic 
burden and increasing absolute numbers in the context of an ageing population equally 
apply to the syndromes of cognitive impairment and in particular, dementia.  Cognitive 
impairment is an umbrella term encompassing everything from mild cognitive 
impairment at one end of the spectrum to dementia at the other end.  Cognitive 
impairment is usually diagnosed on neuropsychological testing comparing performance 
across various cognitive domains against age and sex standardised mean scores.  
Diagnosis of cognitive syndromes, for example dementia, is clinical and usually made 
according to a recognised classification system.    
 
Cognitive impairment has been reported in a variety of cardiovascular disorders. It is 
described in patients with hypertension,3 atrial fibrillation (AF)4 and CAD, especially 
after coronary artery bypass grafting (CABG).5  Many patients with HF, if not most, have 
a history of one or more of these co-morbidities and these could account for cognitive 
impairment in patients with HF.  On the other hand, HF per se might also lead to 
cognitive impairment. Putative mechanisms include cerebral hypoperfusion and 
systemic inflammation.6,7 Thus, there are several plausible reasons to suspect an 
association between HF and cognitive decline.  Central to the treatment of HF is a 
relatively complex multi-drug pharmacological treatment which requires careful 
biochemical surveillance, strict adherence and high level self-management.8  Successful 
self-management may be jeopardised by cognitive impairment. 
 
A literature describing cognitive impairment in HF is available but papers are published 
in disparate specialty medical journals (cardiology, neurology, psychiatry, nursing), 
sample sizes can be modest and results are inconsistent.    In this situation a 
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comprehensive synthesis of all published literature with summary statistics can give 
useful information. 
We aimed to conduct a systematic review and meta-analysis looking at the association 
between HF and cognitive impairment. 
 
Methods 
Our systematic review was designed, conducted and reported according to the 
“Preferred Reporting Items for systematic reviews and meta-analyses” (PRISMA) 
guidelines.9  We created a search protocol, available on an open access web-based 
resource (PROSPERO, registration number CRD42014015485).10   
 
Our primary aim was to describe an association between HF and cognitive impairment 
(where cognitive impairment is a syndrome including mild cognitive impairment, multi-
domain cognitive impairment and varying severities of dementia).  Two independent 
researchers trained in systematic review, performed all aspects of searching, selection,   
extraction and assessment (J.A.C & P.M) any disagreements were referred to a third arbitrator 
(T.J.Q).   
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Inclusion/exclusion criteria 
Our eligibility criteria were defined prior to any literature searches and were outlined 
as follows: 
 
1.   Studies published in English.  
2.   Studies with at least 50 human participants. 
3.   Original research published in peer reviewed scientific journals.  
4.  Studies presenting data on cognitive impairment and HF with the following 
study  designs:  prospective cohorts, cross sectional population studies and case-control 
 studies. 
5.   Studies using at least one validated measure of cognition or clinical diagnosis of a 
 cognitive syndrome made according to recognized criteria.  
6. Studies including patients with a formal clinical diagnosis of HF. 
 
We excluded randomized controlled trials that collected cognitive data as primary or 
secondary outcome as we felt the included participants may not be generalizable to an 
unselected HF population.  Abstracts were included in the search but, for the final 
selection of studies we only included those that had been fully published in peer 
reviewed journals.  Papers were not excluded on the basis of year of publication. 
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 Search strategy 
We created a sensitive search strategy based around concepts of [heart failure] and 
[cognition/dementia/cognitive testing].  Where available we used validated search 
strings and supplemented these with MeSH terms and other controlled vocabulary.  
(figure 1).  We searched multidisciplinary databases from inception until 31st May 2015:  
MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), PsychINFO (EBSCO), Web of 
Science (Thomson Reuters) and CENTRAL (Cochrane Library).  Where the facility was 
available, we used the “explode” function in those databases.  Bibliographies of included 
papers and relevant reviews were searched for further possible titles and the process 
was repeated until no new titles were found.  Where the same data were presented in 
more than one publication we used the primary (first) publication. 
 
After de-duplication, titles generated from the initial database searches were screened 
and if felt to be relevant, then the full text was reviewed.   
 
Data extraction  
For papers eligible for inclusion, we extracted data to a pre-specified and piloted 
proforma.  We collated information regarding diagnosis of HF, with particular focus on 
subtypes of HF (HF with preserved [HF-PEF] or reduced ejection fraction [HF-REF]); 
severity of HF (symptomatic or objective marker); sampling frame (outpatient or 
inpatient/mixed) and cognitive assessment or criteria employed.  
 
Risk of bias and generalizability assessment   
We assessed for internal and external validity using the approach outlined in critical 
appraisal skills (CASP) guidance.9  We used the CASP checklists for cohort and case-
control studies and assessed domains relating to sampling frame, case ascertainment 
(dementia and HF) and confounding to create a semi-quantitative assessment.    We 
defined a paper as low risk of bias where the following criteria were met: samples 
recruited had robust diagnosis of HF based on current ESC guidelines; cognitive 
function was assessed using standardized cognitive assessment tools or diagnosis of a 
cognitive syndrome made using validated classification system; confounding factors 
taken into account in the analyses of results.   For longitudinal studies we identified a 
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follow up period of 18 months to be an appropriate timescale for development of 
cognitive impairment. For each study we considered external validity and whether the 
results could be applied to a contemporary HF population. 
 
Data analyses 
We created summaries of findings into tables to inform a narrative synthesis of the 
included papers. We performed meta-analyses to give summary estimates in those 
instances where more than 3 papers used a similar study design and contained similar 
cognitive assessments.  We assessed heterogeneity through visual inspection of forest 
plots and quantitatively using Higgins I2 and we assessed for potential publication bias 
using a funnel plot.   All meta-analyses were run with both a fixed and random effects 
model.   
 
We pre-specified differing statistical approaches depending on the study design.  For 
case-control data we calculated odds ratios comparing proportions with cognitive 
impairment in the HF population versus the healthy control population.  For cross-
sectional studies we described point estimates of prevalence of cognitive impairment / 
dementia. For prospective studies, we planned to assess rates of incident cognitive 
impairment / dementia and calculate summary hazard ratios.  
 
We pre-specified a sensitivity analysis, restricted to those studies judged as low risk of 
bias on our validity assessment and we pre-specified subgroup analyses restricted to 
outpatient populations only.  
 
All analyses were performed using Stata version 14 (Stata Corp, College Station, Texas).   
 
Results 
From 18000 titles identified, we selected 350 abstracts for review, we assessed 87 full 
manuscripts and 37 papers (n=8411 participants) were eligible for inclusion in the final 
review.  Figure 1. 
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 Narrative review of included studies 
We included 7 case control studies (representing 1781 participants),10-17 4 of which 
included healthy participants as the control group13, 15-17 with the other 3 comparing 
rates of cognitive impairment between HF cohorts i.e. between those with HF-PEF and 
HF-REF.10, 12&14  26 cross-sectional studies were included18-42 (representing 4177 
participants) the majority of which (n=18) recruited patients from the outpatient 
setting.18-21, 24-26, 32-34, 36-43  Only 4 studies (with 2513 participants) examined for incident 
cognitive function / dementia in patients with HF over prospective longitudinal follow 
up.44-47  All key study characteristics are summarised in tables 1- 3. 
 
Available longitudinal studies included ambulatory patients with HF followed for 
between six months and ten years.45, 47 Within the prospective study rubric, various 
study designs were employed including comparison of HF-PEF and HF-REF and 
comparison of HF with healthy controls. The heterogeneity precluded any attempt at 
meta-analysis.  Three studies compared HF and non-HF groups, 44-46 where follow-up 
was longer than two years the HF group seemed to have greater decline in cognition 
although a follow up duration of 9-10 years may be too long to look for differences in 
cognition, given the high 5 year mortality associated with HF.  (Table 4). 
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Quantitative analyses 
Of our eligible studies n=20 (n=2290 participants) cross-sectional20, 24-37, 39-43 and n=5 
(n=1414 participants) case-control were suitable for quantitative summary analyses.13, 
15-17 There was substantial heterogeneity across all analyses (I2: 98.5% for cross-
sectional; 71.5% for case-control) and we preferentially report random effects data.   
 
For cross-sectional studies describing prevalence of cognitive impairment there was a 
spread in reported values from 0.1 (95% CI: 0.07-0.14) to 0.79 (95% CI: 0.75-0.82).  
Summarising the data, the overall prevalence for cross sectional studies was 0.43 (95% 
CI: 0.30-0.55).  For our subgroup analysis restricted to those studies including only 
outpatients (n=14 papers; 1620 participants),20, 24-26, 32-34, 36-37, 39-43 results were similar 
(0.40, 95% CI: 0.28-0.52) as were summary results in our sensitivity analysis restricted 
to low risk of bias studies (n=13 papers; 2012 participants) (0.44, 95% CI:  0.29-0.59).20, 
24-27, 32-37, 39, 43 (Figures 2-4).  We performed a sub group analysis by age using a cut-off 
age of 69 years.  The mean age for all 20 cross-sectional studies was 68 years with a 
median of 69 years.  These results are presented in figure 5 and show a larger effect size 
in those studies with a mean age of >69 years (0.39, 95% CI: 0.26-0.53).  There were 
insufficient studies to allow for our proposed subgroup analysis looking at HF-PEF and 
HF-REF. 
 
For case-controlled studies, n=5 papers (1414 participants) compared rates of cognitive 
impairment and dementia in HF versus non-HF controls.13, 15-17  Overall the random 
effects model showed a 2.64 odds ratio (95% CI:  1.83 - 3.80) of cognitive impairment in 
the HF cohort.  (Figure 6). There were insufficient data to allow us to compare those 
case controlled studies comparing HF-PEF and HF-REF.  
 
A funnel plot showing standard error against point estimate for the cross sectional data 
is shown in figure 7.  This shows a relatively symmetrical funnel shape suggesting 
publication bias was not a major issue. 
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Discussion 
We have demonstrated strong association between HF and cognitive problems.  Our 
summary data suggest that in HF patients recruited into observational studies around 
40% will have cognitive impairment.  Our subgroup and sensitivity analyses confirm 
that this high prevalence is robust and not driven by poor quality studies or by inclusion 
of significant numbers who were unwell with decompensated HF.  Case-control data 
suggest that compared to matched controls with no HF, those with HF have significantly 
increased risk of cognitive impairment.  In fact, as patients with cognitive impairment 
are frequently excluded from studies (e.g. due to inability to provide informed consent 
or inability to complete study assessments) the actual prevalence in the clinical setting 
may be higher than reported here.  
 
Explanation of results 
Observational data are susceptible to a variety of biases.  The variability of the 
prevalence rates for cognitive impairment that are reported in the reviewed studies 
probably results from the differences in the populations studied and the differences in 
the range and specificity of the instruments used to assess cognition.  The heterogeneity 
of samples including patients and control subjects who had previous neurological 
injuries poses an additional limitation on the samples in most of the studies included.     
 
We have shown that cognitive impairment is prevalent.  To look at causation the ideal 
study design would involve longitudinal follow up of a group of patients with HF (but 
free of cognitive impairment at inception) with regular administration of standardised 
cognitive assessment tools and comparison with a group of age-, sex- and education-
matched control cardiac patients as well as healthy control participants.  For completion 
a group of cardiac patients (without HF) should be included to allow us to control for 
underlying cardiac conditions such as AF and CAD.  We found no study that used this 
specific design. 
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Data in context of previous research 
To put our prevalence estimate of 40% into context, the estimated prevalence of 
cognitive impairment / dementia in the UK in adults over 65 years old is 7.1% (based on 
2013 data).  The total number of people with dementia in the UK is forecast to increase 
to over 1 million by 2025 and over 2 million by 2051 if age-specific prevalence remains 
stable.  This increasing prevalence is driven by ageing of the general population and 
existence of other co-morbid factors – of which HF could be an important contributor. 
 
We found 15 additional studies that have been conducted since Vogels et al published 
their systematic review of 22 papers in 2007.48  These additional papers have been 
published since 2006 and all describe the prevalence of cognitive impairment in HF.  In 
this review we therefore provide an up to date synthesis of key studies published in this 
area.  Whether the increased risk of cognitive impairment in HF is due to the clinical 
syndrome of HF itself – or the atherosclerotic risk factors commonly underlying it 
remains less clear.  Other systematic reviews have shown associations between 
cognitive impairment and other cardiovascular disorders such as AF,49 stroke50 and 
CAD.51  Many potential confounding variables are relevant to these groups of patients 
and so although the association with impaired cognition is clear, a causal relationship is 
harder to prove - or disprove.   
 
Strengths of study approach 
The strengths of our review include a comprehensive search strategy based on 
validated search terms and interrogation of cross-disciplinary electronic databases.  All 
papers were quality assessed using a robust method tailored to our specific study 
question.    
 
Limitations of study approach 
Due to lack of information in some of the manuscripts included, we were not able to 
include all of the papers in the pre-specified analyses.  A further limitation of our 
summary analyses is the substantial clinical heterogeneity between studies and 
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participants.  Unfortunately patient level data such as ethnicity and sex were not 
routinely presented in the manuscripts and so further subgroup analyses could not be 
performed.  Excluding 38 studies with fewer than 50 participants and 4 randomised 
controlled trials from this systematic review may also have influenced the results 
presented. 
 
Implications for clinical practice/future research 
Unfortunately, there are few if any data about the effect of therapeutic interventions 
specifically for HF on cognitive function and similarly limited information about the 
efficacy and safety of specific therapies for cognitive impairment in patients with heart 
failure. Indeed, to our knowledge, no completed large trial to date has measured 
cognitive function as an outcome (and most excluded patients with significant known 
cognitive impairment).  
 
The one exception is the new angiotensin receptor neprilysin inhibitor (ARNI), 
sacubitril/valsartan. Because neprilysin is one of the many mechanisms clearing 
amyloid-ß peptides from the brain, there is a theoretical concern regarding the long 
term cognitive effects of neprilysin inhibitors.  There was no increase in cognition-
related adverse events in the sacubitril/valsartan arm of PARADIGM-HF (compared 
with the enalapril arm), although cognitive function was not formally assessed during 
the trial.52  Two ongoing trials of neprilysin inhibitors are collating serial assessments of 
cognition.  The Prospective comparison of ARni with Arb Global Outcomes in heart 
failure with preserved ejectioN fraction trial (PARAGON-HF)53 utilizes MMSE to assess 
cognition while the Prospective Evaluation of cognitive function in heart failure: A 
Randomized double-blind Study in Patients with Preserved Ejection fraction Cardiac 
failure Treated wIth Valsartan or Entresto (PERSPECTIVE), is using a battery of more 
detailed cognitive tests in addition to cerebral positron emission tomography (PET) 
imaging for amyloid.54   
 
Drugs that are used to treat cognitive impairment include the acetylcholinesterase 
inhibitors (ACHI) donepezil, rivastigmine and galantamine and the NMDA receptor 
Page 12 of 31
antagonist memantine.  Adverse cardiovascular events with these drugs are very 
uncommon. However, there is some evidence that ACHI therapy is associated with 
increased risk of bradycardia, sick sinus syndrome, heart block and syncope which 
means caution is necessary when these agents are combined with beta-blockers, 
ivabradine and digoxin. Rarely, torsades de pointes may occur because of QT 
prolongation and again caution is needed when ACHIs are combined with other drugs 
affecting the QT interval such as amiodarone, ivabradine and certain antipsychotics, 
antidepressants and antimicrobials. Hypokalemia should also be avoided.   
 
One recent study showed donepezil to be safe in patients without symptomatic heart 
disease and actually reduced levels of plasma BNP in patients with subclinical HF.55 
Further research is needed to fully understand the effects of these drugs in patients 
with heart failure.  Little is known about the cardiovascular effects of memantine but 
there have been reports of bradycardia and reduced cardiovascular survival associated 
with its use.56 
 
Although the idea of concomitant cognitive impairment and HF will be familiar to most 
clinicians it is not routinely screened for in the cardiology outpatient setting.  Cognitive 
screening is not currently recommended in the European Society of Cardiology heart 
failure guidelines and this is in part due to the lack of standardised screening tools that 
are accessible, easy to administer in a timely fashion and that have clear clinical cut-off 
scores.  Although this systematic review clearly shows a high prevalence of cognitive 
impairment in the HF population recent observational data suggest that informal 
assessment of cognition by a cardiologist is insufficiently sensitive with 3 in 4 patients 
with cognitive impairment not recognised as such in routine consultations. Cognitive 
assessment tools may have a role in research and practice, although first we should 
reach a consensus on appropriate assessment score cut-offs in this population and 
outline specific cognitive profiles in these patients. Although clearly important, 
systematic data on cognitive impairment in HF does not remove the need for 
prospective studies and experimental models to clarify the pathogenesis of this 
condition.   
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To progress our understanding we recommend increasing use of cognitive assessment 
using standardised screening tools in future HF studies. Although we found numerous 
studies assessing prevalence, there is a dearth of studies investigating the incidence of 
CI in HF. Once the incidence and prevalence of CI in HF are better defined we need to 
evaluate the consequences of CI in HF.  Identifying underlying mechanisms for CI in HF 
may present targets for intervention, the 'holy grail' of cognitive research. A number of 
processes have been postulated, and we now need confirmatory studies using new 
developments in neuroimaging and biomarkers in representative populations of HF 
patients. All of this will require a multidisciplinary approach between HF and dementia 
research teams.  
 
In conclusion, much of the heterogeneity in the prevalence of cognitive impairment / 
dementia seen in the HF population can be explained by differences in study 
methodology and case mix.  Although we found numerous studies assessing prevalence, 
there is a dearth of studies investigating the incidence of cognitive impairment in HF 
which should be addressed in future research. Once the incidence and prevalence of 
cognitive impairment in HF are better defined we then need to evaluate the 
consequences of cognitive impairment in HF and identify its underlying mechanisms.  
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Figure 1.  Search strategy and review profile for the systematic review of cognitive impairment and 
heart failure 
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Figure 2.  Forest plot showing fixed and random effects for all cross sectional studies 
 
 
  Figure 3.  Forest plot showing fixed and random effects for all cross sectional studies with 
outpatient sampling 
 
  
Study name Subgroup within study Statistics for each study Point estimate and 95% CI
Point Lower Upper Relative Relative 
estimate limit limit weight weight
Alosco 2013 outpatient 0.30 0.23 0.37 5.04
Athilingham 2011 outpatient 0.17 0.10 0.24 5.04
Baldasseroni 2010 outpatient 0.45 0.34 0.56 2.22
Cacciatore 1998 outpatient 0.57 0.54 0.60 27.46
Gallagher 2013 outpatient 0.22 0.16 0.28 6.87
Garcia 2011 outpatinet 0.11 0.07 0.15 15.45
Ghanbari 2013 outpatient 0.65 0.59 0.71 6.87
Harkness 2013 outpatient 0.73 0.63 0.83 2.47
Hawkins 2014 outpatient 0.33 0.28 0.38 9.89
Heljm 2012 outpatinet 0.22 0.16 0.28 6.87
Jesus 2006 outpatient 0.20 0.13 0.27 5.04
Miller 2012 outpatient 0.62 0.54 0.70 3.86
Steinberg 2011 outpatient 0.44 0.31 0.57 1.46
Vogels 2007 outpatient 0.24 0.11 0.37 1.46
0.38 0.36 0.39
-1.00 -0.50 0.00 0.50 1.00
Meta Analysis
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Figure 4.  Forest plot showing fixed and random effects for cross sectional studies with low risk of 
bias 
 
  
Study name Subgroup within study Statistics for each study Point estimate and 95% CI
Point Lower Upper Relative Relative 
estimate limit limit weight weight
Alosco 2013 Low risk of bias 0.30 0.23 0.37 4.69
Athilingham 2011 Low risk of bias 0.17 0.10 0.24 4.69
Baldasseroni 2010 Low risk of bias 0.45 0.34 0.56 2.06
Cacciatore 1998 Low risk of bias 0.57 0.54 0.60 25.53
Cameron 2010 Low risk of bias 0.73 0.63 0.83 2.30
Gallagher 2013 Low risk of bias 0.22 0.16 0.28 6.38
Garcia 2011 Low risk of bias 0.11 0.07 0.15 14.36
Ghanbari 2013 Low risk of bias 0.65 0.59 0.71 6.38
Hadjuk 2013 Low risk of bias 0.32 0.28 0.36 14.36
Harkness 2013 Low risk of bias 0.73 0.63 0.83 2.30
Hawkins 2014 Low risk of bias 0.33 0.28 0.38 9.19
Heljm 2012 Low risk of bias 0.22 0.16 0.28 6.38
Vogels 2007 Low risk of bias 0.24 0.11 0.37 1.36
0.38 0.36 0.39
-1.00 -0.50 0.00 0.50 1.00
Meta Analysis
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Figure 5.  Forest plots showing fixed and random effects for cross sectional studies with median age 
<69 years compared to cross sectional studies with median age >69 years. 
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Figure 6.  Forest plot showing fixed and random effects for case controlled studies (heart failure vs. 
no heart failure) 
 
 
 
Figure 7.  Funnel plot of standard error by point estimate 
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Tables 1 -3:  Study design 
Table 1.  Design  of case-controlled studies  
 Study  Sample  Population  CV 
Measures/Criteria 
 Cognitive assessment 
tool used 
 Bauer et al 
201111 
  
 51 HF-REF patients 
 29 HF-PEF patients 
 Outpatients only  LVEF 
 NYHA 
 RBANS  
 Neuropsychological 
battery 
 Bratzke-Bauer 
et al 201312 
 47 HF-REF patients 
 33 HF-PEF patients 
 Outpatients only  LVEF 
 NYHA 
  
 MMSE 
 RBANS 
 Neuropsychological 
battery  
 Callegari et al 
200213 
 64 HF patients 
 321 healthy control 
participants 
 Consecutive 
admissions 
 LVEF<50% 
 NYHA I-III 
 CPET 
 Right heart 
catheterisation 
 Neuropsychological 
battery 
 Festa et al 
201114 
  
 169 HF-REF patients 
 38 HF-PEF patients 
 Outpatients only  LVEF  Neuropsychological 
battery 
 Pressler et al 
201015 
  
  
 249 HF patients 
 63 healthy control 
participants 
 102 general medical 
patients 
 Outpatients only  NYHA 
 LVEF 
 MMSE 
 Neuropsychological 
battery 
 Sauvé et al 
200916 
 50 HF patients 
 50 healthy control 
participants 
 Outpatients only  LVEF≤40% 
 NYHA II-IV 
 Neuropsychological 
battery 
 Trojano et al 
200317 
 149 HF NYHA II patients 
 159 HF NYHA III/IV 
patients 
 207 non HF control 
patients 
 Consecutive 
admissions 
 No measure of 
LV function 
 NYHA II-IV 
 MMSE 
 Neuropsychological 
battery 
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Table 2.  Design of cross-sectional studies 
 Study  Sample  Pop
ulation 
 Ag
e 
 (y
ears) 
 CV Measures 
 /Criteria 
 Cognitive assessment tool 
used 
 Alosco et al 201418 
  
 110 CHF pts  Outp
atients 
 70 
(9) 
 LVEF 
 NYHA II-IV 
 3MS 
  
Alosco et al 201219 
  
 157 CHF pts  Outp
atients 
 69 
(10) 
 2 minute step test 
 NYHA 
 Neuropsychological battery 
 Alosco et al 201320 
  
 52 CHF pts  Outp
atients 
 66 
(9) 
 Cardiac Index  MMSE 
 RBANS 
 Alosco et al 201421 
  
 179 CHF pts  Outp
atients 
 68 
(10) 
 LVEF 
 NYHA II-IV 
 Neuropsychological battery 
 Antonelli et al 200322  369 CHF pts  Cons
ecutive 
admissions 
 77 
(7) 
 NYHA  MMSE 
 Neuropsychological battery 
 Arslanian- Engoren et al 
201423 
 53 CHF pts  Inpat
ients 
 72 
(5) 
 NYHA  Cogstate battery 
  
 Athilingam et al 201124 
  
 90 CHF pts  Outp
atients 
 62 
(9) 
 NYHA 
 LVEF 
 Cardiac index & 6 minute walk test 
 MMSE 
 MoCA 
 Baldasseroni et al 201025 
  
  
 80 CHF pts  Outp
atients 
 72 
(6) 
 NYHA 
 6 minute walk test 
 LVEF 
 MLHFQ 
 MMSE 
  
 Cacciatore et al 199826  92 CHF participants  Outp
atients 
 74 
(6) 
 NYHA  MMSE 
 Cameron et al 201027 
  
 93 CHF pts  Cons
ecutive 
admissions 
 73 
(11) 
 LVEF 
 NYHA 
 Self-care HF index 
 MMSE 
 MoCA   
 Debette et al 200728  83 HF pts  Cons
ecutive 
admissions 
 62  LVEF<45% 
 NYHA I-IV 
 MMSE 
 Dodson et al 201329 
  
 282 Decompensated HF 
pts 
 Non-
consecutive 
admissions 
 80 
(8) 
 HF diagnosis based on 
documentation in medical records 
 MMSE 
 Feola et al 200730  60 CHF pts  Inpat
ients 
 66  LVEF 
 NYHA II-IV 
 BNP 
  
 Neuropsychological battery 
 Feola et al 201331 
  
 303 CHF pts 
  
 Cons
ecutive 
 72 
(10) 
 LVEF 
 NYHA 
 MMSE 
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  admissions  BNP 
 6 minute walk test 
 Non-invasive CO 
  
 Gallagher et al 201332  128 CHF pts  Outp
atients 
 81  NYHA 
 MLHFQ 
 MoCA 
 Garcia et al 201133  116 CHF  Outp
atients 
 69 
(9) 
 NYHA 
 2 minute step test 
 3MS 
 Neuropsychological battery 
 Ghanbari et al 201334  239 CHF pts  Outp
atients 
 59 
(10) 
 NYHA 
 LVEF 
 MMSE 
  
 Hajduk et al 
 201335 
 577 CHF pts  Inpat
ients 
 71  Not specified  MoCA 
 Neuropsychological battery 
 Harkness et al 201336  100 CHF pts  Outp
atients 
 72 
(10) 
 LVEF ≤45% 
 NYHA I-III 
 Self-care in HF index 
 MMSE 
 MoCA 
  
 Hawkins et al 201437  231 CHF pts  Outp
atients 
 69 
(7) 
 NYHA  Neuropsychological battery 
 Hawkins et al 201238  250 CHF pts  Outp
atients 
 66 
(10) 
 LVEF  RBANS 
 Neuropsychological battery 
 Hjelm et al 201339 
  
 137 CHF pts  Outp
atients 
 72  NYHA 
 LVEF 
 BNP 
 MMSE 
 Neuropsychological battery 
 Jesus et al 200640  83 CHF pts  Outp
atients 
 55 
(12) 
 LVEF  MMSE 
 Miller et al 201241  140 HF pts  Outp
atients only 
 69 
(9) 
 No measure of LV function 
 No NYHA classification 
 2 minute step test 
 Neuropsychological battery                                               
 Steinberg et al 201142  55 HF pts  Outp
atients only 
 55 
(8) 
 LVEF≤45% 
 NYHA I-III 
 6 Minute Walk Test 
 MMSE 
 Neuropsychological battery 
 Vogels et al 200743 
  
 58 CHF pts  Outp
atients 
 69 
(9) 
 LVEF 
 NYHA 
 MMSE 
 Neuropsychological battery 
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Table 3.  Design of longitudinal studies 
 Study  Sample  Populati
on 
 CV Measures /Criteria  Cognitive 
assessment tool used 
 Fo
llow up 
period 
 Almeida 
et al 201244 
  
 77 CHF pts with LVEF <40% 
 73 CAD pts with LVEF >60% 
 81 controls with no CAD/CHF 
 Outpatie
nts 
 LVEF 
 6 minute walk test 
 MMSE 
 Neuropsychologic
al battery 
  
 24 
months 
 Hjelm et 
al 201245 
  
 95 HF pts 
 607 non-CHF controls 
 Outpatie
nts 
 HF diagnosis based on 
documentation in medical 
records 
 Neuropsychologic
al battery 
 10 
years 
 Qiu et al 
200646 
  
 205 CHF pts 
 1096 controls 
  
 Outpatie
nts 
 Not specified  MMSE  9 
years 
 Riegel et 
al 201247 
 279 consecutive  
 HF pts (HF-REF & HF-PEF) 
 Outpatie
nts 
 NYHA I-IV 
 LVEF  
 Neuropsychologic
al battery 
  
 6 
months 
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Table 4:  Results from longitudinal studies 
Study Sample Age 
(Years) 
Relative Risk 95% CI Follow up  
period 
Change over time 
Almeida et al 
201244 
 
77 CHF pts with LVEF <40% 
73 CAD pts with LVEF >60% 
81 controls with no CAD/CHF 
68 (10) 
68 (10) 
69 (11) 
N/A N/A 24 months CAMCOG scores in CHF group declined by 0.9 points over 
2 years 
 
No other differences between groups 
Hjelm et al 
201245 
 
95 HF pts 
607 non-CHF controls 
84(3) 1.258 0.952 – 1.661 10 years HF patients: Significant decline in episodic memory & 
spatial performance compared with controls. 
Qiu et al 
200646 
 
 
 
205 CHF pts 
1096 Controls  
83 (5) 
81 (5) 
0.878 0.765 – 1.007 9 years Over 9 years 53% CHF patients developed CI & 61% of 
controls developed CI 
 
 
Riegel et al 
201247 
 
279 consecutive  
HF pts  (HF-REF & HF-PEF) 
62 (12) N/A N/A 6 months No significant change in cognition over 6 months (HF-REF 
and HF-PEF) 
 
Minimal improvement in DSST (53 (18)- 58 (18)) in both 
groups likely due to learned effect 
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